Neuren Pharmaceuticals Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Neuren Pharmaceuticals de 5.2% y 13.5% por año respectivamente. Se prevé que el BPA crezca en un 4.9% al año. Se espera que la rentabilidad financiera sea de 34.6% en 3 años.

Información clave

1.4%

Tasa de crecimiento de los beneficios

1.0%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	33.1%
Tasa de crecimiento de los ingresos	10.5%
Rentabilidad financiera futura	31.0%
Cobertura de analistas	Good
Última actualización	28 May 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Might Deserve Your Attention Today

May 31

Getting In Cheap On Neuren Pharmaceuticals Limited (ASX:NEU) Is Unlikely

May 03

An Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 41% Undervalued

Apr 01

Forecast: Analysts Think Neuren Pharmaceuticals Limited's (ASX:NEU) Business Prospects Have Improved Drastically

Mar 05

Here's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of Investors

Mar 02

Neuren Pharmaceuticals Limited's (ASX:NEU) 51% Jump Shows Its Popularity With Investors

Dec 18

Need To Know: Analysts Are Much More Bullish On Neuren Pharmaceuticals Limited (ASX:NEU) Revenues

Sep 02

Calculating The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Aug 31

This Just In: Analysts Are Boosting Their Neuren Pharmaceuticals Limited (ASX:NEU) Outlook for This Year

Mar 03

Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business

Jan 07

We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

Sep 06

Companies Like Neuren Pharmaceuticals (ASX:NEU) Can Afford To Invest In Growth

May 31

We're Not Worried About Neuren Pharmaceuticals' (ASX:NEU) Cash Burn

Feb 03

Here's Why We're Not At All Concerned With Neuren Pharmaceuticals' (ASX:NEU) Cash Burn Situation

Aug 06

We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

May 05

Independent Non-Executive Chairman Patrick Donald Davies Just Bought 21% More Shares In Neuren Pharmaceuticals Limited (ASX:NEU)

Feb 19

Have Insiders Been Selling Neuren Pharmaceuticals Limited (ASX:NEU) Shares This Year?

Jan 04

Previsiones de crecimiento de beneficios e ingresos

ASX:NEU - Estimaciones futuras de los analistas y datos financieros pasados (AUD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	286	167	186	136	6
12/31/2025	172	99	127	120	6
12/31/2024	152	91	76	92	6
12/31/2023	232	157	185	185	N/A
9/30/2023	155	106	120	120	N/A
6/30/2023	78	55	54	54	N/A
3/31/2023	47	28	29	29	N/A
12/31/2022	15	0	4	4	N/A
9/30/2022	9	-3	-3	-3	N/A
6/30/2022	3	-7	-10	-10	N/A
3/31/2022	3	-7	-10	-10	N/A
12/31/2021	3	-8	-10	-10	N/A
9/30/2021	2	-10	-10	-10	N/A
6/30/2021	1	-12	-9	-9	N/A
3/31/2021	1	-11	-9	-9	N/A
12/31/2020	1	-9	-8	-8	N/A
9/30/2020	1	-8	-9	-9	N/A
6/30/2020	0	-8	-9	-9	N/A
3/31/2020	0	-9	-10	-10	N/A
12/31/2019	0	-11	-12	-12	N/A
9/30/2019	7	-6	-5	-5	N/A
6/30/2019	14	-1	2	2	N/A
3/31/2019	14	1	4	4	N/A
12/31/2018	14	3	6	6	N/A
9/30/2018	7	3	0	0	N/A
6/30/2018	1	3	-6	-6	N/A
3/31/2018	1	3	-6	-6	N/A
12/31/2017	1	3	-6	-6	N/A
9/30/2017	2	-2	N/A	-7	N/A
6/30/2017	3	-8	N/A	-8	N/A
3/31/2017	3	-10	N/A	-10	N/A
12/31/2016	3	-12	N/A	-12	N/A
9/30/2016	2	-14	N/A	-14	N/A
6/30/2016	0	-15	N/A	-17	N/A
3/31/2016	1	-14	N/A	-15	N/A
12/31/2015	2	-13	N/A	-13	N/A
9/30/2015	2	-11	N/A	-11	N/A
6/30/2015	3	-9	N/A	-8	N/A
3/31/2015	3	-9	N/A	-7	N/A
12/31/2014	3	-8	N/A	-6	N/A
9/30/2014	3	-10	N/A	-7	N/A
6/30/2014	3	-12	N/A	-7	N/A
3/31/2014	4	-11	N/A	-7	N/A
12/31/2013	5	-10	N/A	-7	N/A
9/30/2013	5	-9	N/A	-7	N/A
6/30/2013	5	-6	N/A	-5	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (0.8% por año) de NEU está por debajo de la tasa de ahorro (2.3%).

Beneficios vs. Mercado: Se prevé que los beneficios (5.2% al año) de NEU crezcan menos que el mercado Australian (13.4% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de NEU crezcan, pero no significativamente.

Ingresos vs. Mercado: Se prevé que los ingresos (13.5% al año) de NEU crezcan más rápidamente que los del mercado Australian (4.7% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 13.5% al año) de NEU crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de NEU sea alta dentro de 3 años (34.6%)

Neuren Pharmaceuticals Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target increased by 7.9% to AU$28.19

Consensus revenue estimates increase by 15%

Price target increased by 27% to AU$24.22

Consensus EPS estimates fall by 11%

Price target increased by 18% to AU$19.14

Consensus revenue estimates increase by 24%

Recent updates

Investor sentiment deteriorates as stock falls 15%

Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Might Deserve Your Attention Today

Price target increased by 7.9% to AU$28.19

Neuren Phase 2 Trial Shows Significant Improvements in Pitt Hopkins Syndrome

Getting In Cheap On Neuren Pharmaceuticals Limited (ASX:NEU) Is Unlikely

Neuren Pharmaceuticals Limited, Annual General Meeting, May 28, 2024

An Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 41% Undervalued

Consensus revenue estimates increase by 15%

Forecast: Analysts Think Neuren Pharmaceuticals Limited's (ASX:NEU) Business Prospects Have Improved Drastically

Here's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of Investors

Neuren Pharmaceuticals Limited to Report Q4, 2023 Results on Feb 29, 2024

Neuren Pharmaceuticals Limited's (ASX:NEU) 51% Jump Shows Its Popularity With Investors

Price target increased by 27% to AU$24.22

Investor sentiment improves as stock rises 40%

Consensus EPS estimates fall by 11%

Investor sentiment improves as stock rises 20%

Now 23% undervalued after recent price drop

Price target increased by 18% to AU$19.14

Now 20% undervalued after recent price drop

Consensus revenue estimates increase by 24%

Need To Know: Analysts Are Much More Bullish On Neuren Pharmaceuticals Limited (ASX:NEU) Revenues

Now 25% undervalued after recent price drop

Calculating The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Neuren Pharmaceuticals Limited Reiterates Net Sales Guidance for the Third Quarter of 2023

Neuren Pharmaceuticals Limited to Report First Half, 2023 Results on Aug 28, 2023

Now 21% undervalued

Consensus EPS estimates fall by 12%

Price target increased by 8.3% to AU$15.07

Independent Non-Executive Director recently sold AU$15m worth of stock

Consensus revenue estimates increase by 12%, EPS downgraded

Price target increased by 18% to AU$10.60

Consensus EPS estimates fall by 14%

This Just In: Analysts Are Boosting Their Neuren Pharmaceuticals Limited (ASX:NEU) Outlook for This Year

Price target increased by 12% to AU$8.99

Neuren Pharmaceuticals Limited Announces Prader-Willi Syndrome IND for NNZ-2591 Approval by FDA

Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business

Neuren Pharmaceuticals Submits Investigational New Drug & First Patients Complete Phase 2 Trials

Price target increased to AU$7.83

Price target increased to AU$7.83

Price target increased to AU$7.37

Neuren Pharmaceuticals Reports Rett Syndrome New Drug Application Accepted for Priority Review by US Food and Drug Administration

We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

Neuren Pharmaceuticals Limited Commences Phase 2 Trials of NNZ-2591 in PMS and PTHS

Consensus estimates of losses per share improve by 47%

Price target increased to AU$6.62

Neuren Pharmaceuticals Limited Commences Phase 2 Trial of NNZ-2591 in Angelman

Neuren Pharmaceuticals Appoints Liza A. Squires as Chief Medical Officer in United States

Companies Like Neuren Pharmaceuticals (ASX:NEU) Can Afford To Invest In Growth

Forecast breakeven date pushed back to 2023

Forecast breakeven date pushed back to 2023

Neuren Pharmaceuticals Limited Receives FDA Approval for Angelman IND and Phase 2 Trial

Consensus forecasts updated

We're Not Worried About Neuren Pharmaceuticals' (ASX:NEU) Cash Burn

Independent Non-Executive Director recently bought AU$59k worth of stock

Neuren Pharmaceuticals Submits Investigational New Drug Application to the US Food and Drug Administration for NNZ-2591

Neuren Pharmaceuticals Limited announced that it expects to receive AUD 20.000001 million in funding

Neuren Pharmaceuticals Limited Submits an Investigational New Drug (IND) Application to the US Food and Drug Administration (FDA) for NNZ-2591 to Treat Angelman Syndrome

Here's Why We're Not At All Concerned With Neuren Pharmaceuticals' (ASX:NEU) Cash Burn Situation

High number of new directors

Independent Non-Executive Chairman recently bought AU$61k worth of stock

Neuren Pharmaceuticals Limited Receives Clear and Constructive Guidance from the Fda Office of Neuroscience in preIND Meetings for Phase 2 Clinical Trials of Nnz2591

We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

Neuren Successfully Completes Drug Substance Manufacturing for NNZ-2591 Phase 2 Trials

Independent Non-Executive Chairman Patrick Donald Davies Just Bought 21% More Shares In Neuren Pharmaceuticals Limited (ASX:NEU)

Independent Non-Executive Chairman recently bought AU$50k worth of stock

Neuren Pharmaceuticals Limited Adds Prader-Willi Syndrome to Pipeline with Compelling Results for NNZ-2591 in Pre-Clinical Model

New 90-day high: AU$1.49

European Commission Grants 3 NNZ-2591 Orphan Designations to Neuren Pharmaceuticals

New 90-day high: AU$1.42